Search or
𝛼SK
𝛼SKbullish
Aardvark Therapeutics (AARD): Obesity Related Biotech Seeking $85m After Setting Terms for IPO
289 Views07 Feb 2025 06:14
Aardvark Therapeutics sets terms for IPO, seeking up to $85m. Developing small-molecule therapeutics for metabolic diseases, with lead product in Phase 3 trial for hyperphagia in PWS.
What is covered in the Full Insight:
- Introduction to Aardvark Therapeutics
- IPO Details and Terms
- Product Candidates and Clinical Trials
- Leadership and Investment Background
- Market Position and Investor Commentary
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Aardvark Therapeutics (AARD) Six Month Summary: A Cold Debut That Froze the Biotech Market19 Aug 2025
- Aardvark Therapeutics (AARD): Obesity Biotech Busts; IPO Trades Deeply in the Red14 Feb 2025
- Aardvark Therapeutics (AARD): Caution Needed Ahead of Small-Cap Obesity Biotech IPO12 Feb 2025
- Aardvark Therapeutics (AARD): Peeking at the Prospectus of Another Obesity-Related IPO28 Jan 2025
- Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation28 Jan 2025
x